Znn3bq.jpeg
²é¿´: 2118  |  »Ø¸´: 8

mollyzhang

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

[½»Á÷] FDAÅú׼ǿÉúCanagliflozinÓÃÓÚ2ÐÍÌÇÄò²¡ ÒÑÓÐ7È˲ÎÓë

2013Äê1ÔÂ11ÈÕѶ /ÉúÎï¹ÈBIOON/ --Ç¿ÉúÆìϵÄÑîÉ­ÖÆÒ©¹«Ë¾10ÈÕÐû²¼£¬ÆäÌÇÄò²¡Ò©Îïcanagliflozin£¨ÉÌÆ·Ãû INVOKANA™£©»ñµÃFDAר¼ÒίԱ»á10£º5Í¶Æ±ÍÆ¼öÅú×¼£¬ÓÃÓÚÖÎÁƳÉÈË2ÐÍÌÇÄò²¡¡£

CanagliflozinÊÇÒ»ÖÖSGLT2ÒÖÖÆ¼ÁÒ©ÎÄÜͨ¹ý½«ÆÏÌÑÌÇ·Ö½âºóͨ¹ýÉöÔàÅųöÌåÍâµÄ·½Ê½À´½µµÍѪÌÇ£¬¾ßÓйãÀ«Ç°¾°¡££¨ÉúÎï¹ÈBioon.com£©

20130111101812190.png

FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes
RARITAN, NJ, January 10, 2013 ¨C Janssen Research & Development, LLC (Janssen) announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 ¨C 5 to recommend approval for canagliflozin, proposed trade name INVOKANA™, to treat type 2 diabetes in adult patients based on the efficacy and safety results from its comprehensive clinical development program.

Canagliflozin is an investigational, oral, once-daily medication for the treatment of adult patients with type 2 diabetes. If approved by the FDA later this year, it would be the first in this new class of diabetes therapies available in the U.S. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people who do not have diabetes, which may contribute to elevated glucose levels. Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in people with diabetes who have elevated blood glucose levels.

¡°We are pleased with the positive recommendation from the committee and look forward to working with the FDA to bring this important new therapy to patients in the U.S. to help them manage their type 2 diabetes,¡± said Peter Stein, M.D., Head, Metabolism Development, Diabetes Disease Area Leader, Janssen. "Today¡¯s outcome represents an important step toward achieving that goal."

Data presented at today¡¯s advisory committee meeting included results from the comprehensive global Phase 3 clinical program, which enrolled 10,285 patients in nine studies; it is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. Canagliflozin was evaluated at 100 mg and 300 mg once-daily doses in placebo- and active comparator-controlled studies, as well as three large studies in special populations: older patients, patients with moderate renal impairment, and patients who had or were at risk for cardiovascular disease. Results showed that in addition to the improvements in glycemic control, both doses of canagliflozin were associated with weight loss and reductions in blood pressure across clinical studies.

Canagliflozin was generally well tolerated. It has specific safety and tolerability issues that were well characterized in this development program (such as the genital mycotic infections, urinary tract infections) and can be well managed by the physician and by the patient for some of these issues.

Janssen presented data from Phase 3 studies at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) in Barcelona in November.

The FDA will consider the advisory committee recommendation in its review of the New Drug Application (NDA) for canagliflozin that was submitted by Janssen on May 31, 2012, though the FDA is not bound to follow it.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. and its affiliates have marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand, and parts of Asia.

[ Last edited by mollyzhang on 2013-1-12 at 12:52 ]
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zjutwangdong

гæ (ÕýʽдÊÖ)

ѧϰ¡¢·ÖÏí¡¢½»Á÷
2Â¥2013-01-12 13:12:55
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

achunok

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

´ÓʮƷ

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÒýÓûØÌû:
2Â¥: Originally posted by zjutwangdong at 2013-01-12 13:12:55
¶¥Ò»¸ö£¡

Â¥ÉÏСÅóÓÑÊÇҩѧԺ¡¢Éú»·»¹ÊÇ»¯²ÄµÄ£¿
һͷ³ÔÅ£µÄܳ
3Â¥2013-01-12 15:24:03
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

h_chen

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ºÏ³ÆµÄÄѶȺܴó£¬ÔÓÖÊÑо¿ÒªºÄ·ÑºÜ´óÎïÁ¦
ѧÉúµ½ÆóÒµÈËת±äÖÐ
4Â¥2013-01-12 16:52:13
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


»¹Ã»ÕýʽÅú×¼

[ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
5Â¥2013-01-12 16:58:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÄäÃû

Óû§×¢Ïú (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
±¾Ìû½öÂ¥Ö÷¿É¼û
6Â¥2013-01-13 14:14:35
ÒÑÔÄ   ÉêÇëDRDEPI   »Ø¸´´ËÂ¥   ±à¼­   ²é¿´ÎÒµÄÖ÷Ò³

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÒýÓûØÌû:
6Â¥: Originally posted by 0616lxk3950 at 2013-01-13 14:14:35
Õâ¸öÒ©Îï×îÔç·¢ÏÖÊÇʲôʱºò£¬ÓÐûÓйýʱѽ

Expert Opinion on Investigational DrugsÉϵÄ×ÛÊö·¢±íÓÚ2007Ä꣬×öÀàÒ©µÄÈÈÃÅʱ¼äÓ¦¸ÃÍùÇ°ÍÆ£¬¶¼¹ýÈ¥Õâô¶àÄêÁË£¬×öme-tooÒ©Îï¿Õ¼äºÜС£¬Ö÷ÒªÊÇÕâÀà½á¹¹²»Ì«ÈÝÒ׸ÄÔ죬³ý·ÇÄãÓкõÄidea
7Â¥2013-01-13 14:49:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xjxiaojing

Í­³æ (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
»¹Ã»Åú׼Ĩ£¬FDA¹ÙÍøÉÏ»¹Ã»ÓÐÅú×¼ÏûÏ¢
Éú»î¶à×˶à²Ê£¬µÀ·Æéá«£¬ÐèÔÙ½ÓÔÙÀ÷
8Â¥2013-01-14 16:13:10
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hoc2h2

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

Dr.

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
sglt2µÄ´ó²¿·Öcandidate¶¼ÔÚpkºÍside effectÉϳöÁËÎÊÌ⣬Õâ»ØÓ¦¸ÃÊÇÒªÅúÁË
ÂÔͨÓлú£¬ÉÔ¶®×öÒ©¡£
9Â¥2013-01-14 22:35:45
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ mollyzhang µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 272·Ö²ÄÁÏ×ÓÇóµ÷¼Á +14 Loy0361 2026-04-10 16/800 2026-04-10 15:23 by MOF_Catal
[¿¼ÑÐ] Ò»Ö¾Ô¸211£¬»¯Ñ§310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á +17 ŬÁ¦·Ü¶·112 2026-04-08 17/850 2026-04-10 12:17 by pengliang8036
[¿¼ÑÐ] Çóµ÷¼Á +9 ôæôæÒ»ÊéÉú 2026-04-09 9/450 2026-04-10 11:43 by wp06
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤300Çóµ÷¼Á +30 Ф¿ªÎÄ 2026-04-09 32/1600 2026-04-10 10:59 by ×ÏÒí¾«Áé
[¿¼ÑÐ] »¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð 5+11 »¯¹¤ÈË999 2026-04-09 42/2100 2026-04-10 09:42 by 690616278
[¿¼ÑÐ] Çóµ÷¼Á288 +5 ioodiiij 2026-04-10 6/300 2026-04-10 09:10 by potatoÃÃ
[¿¼ÑÐ] 312Çóµ÷¼Á +3 Àîºè·É·É 2026-04-06 3/150 2026-04-09 17:32 by wp06
[¿¼ÑÐ] 327Çóµ÷¼Á +10 Xxjc1107. 2026-04-06 11/550 2026-04-09 01:21 by lature00
[¿¼ÑÐ] Çóµ÷¼Á +13 Æâluck 2026-04-07 13/650 2026-04-08 22:46 by Öí»á·É
[¿¼ÑÐ] 0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö +23 haaaabcd 2026-04-05 26/1300 2026-04-08 16:19 by luoyongfeng
[¿¼ÑÐ] 274Çóµ÷¼ÁÇóµ÷¼Á +10 Jachenbingoo 2026-04-06 13/650 2026-04-08 14:25 by zhq0425
[¿¼ÑÐ] ¿¼Ñе÷¼Á +3 WwwwwwwÍÛ 2026-04-06 3/150 2026-04-06 20:55 by lbsjt
[¿¼ÑÐ] 26×ÔÈ»µØÀíѧ303·ÖÇóµ÷¼Á +4 Ò»Õ½³É˶°¡°¡°¡° 2026-04-06 9/450 2026-04-06 20:35 by lin-da
[¿¼ÑÐ] Çóµ÷¼Á +4 wos666 2026-04-03 5/250 2026-04-06 15:22 by wos666
[¿¼ÑÐ] 327Çóµ÷¼Á +4 ʰ¹âÈÎȾ 2026-04-05 4/200 2026-04-05 20:16 by ÄϺ½~ÍòÀÏʦ
[¿¼ÑÐ] 358Çóµ÷¼Á +7 Çïgk 2026-04-04 7/350 2026-04-05 13:29 by huangmoli
[¿¼ÑÐ] 353Çóµ÷¼Á +10 MayUxw1 2026-04-03 10/500 2026-04-05 09:23 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +12 19123253302 2026-04-04 12/600 2026-04-05 08:08 by 544594351
[¿¼ÑÐ] 295Çóµ÷¼Á +4 AÄãºÃÑо¿Éú 2026-04-04 5/250 2026-04-04 22:46 by yu221
[¿¼ÑÐ] ²ÄÁÏרҵ383Çóµ÷¼Á +8 ¹ùÑôÑôÑô³É 2026-04-03 8/400 2026-04-04 10:29 by Rednal.
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û